Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.Elotuzumab is a compound that directly activates NK cells and induces antibody-dependent cytotoxicity, and can be used in combination with lenalidomide and dexamethasone (Ld) to treat multiple myeloma.

Elotuzumab (anti-SLAMF7) was given at 10 mg/kg weekly for the first two treatment cycles (28 days/cycle), followed by 10 mg/kg every other week for all subsequent cycles. Four different Elotuzumab (anti-SLAMF7) combination therapies were administered: 1) Elotuzumab (anti-SLAMF7) and dexamethasone 2) Elotuzumab (anti-SLAMF7), lenalidomide and dexamethasone 3) Elotuzumab (anti-SLAMF7), pomalidomide and dexamethasone and 4) Elotuzumab (anti-SLAMF7), carfilzomib, pomalidomide, and dexamethasone. We found that regardless of Elotuzumab (anti-SLAMF7) combination therapy, all patients treated showed decreased phosphorus levels after initiating Elotuzumab (anti-SLAMF7) treatment with reductions ranging from 12.5% to 44.1% below baseline. Six participants (67%) demonstrated average serum phosphorus at or below 2.5 mg/dL after starting Elotuzumab (anti-SLAMF7) therapy.[2]